Mirabegrón Stada (Mirabegron)

Mirabegron selectively stimulates β3‑adrenergic receptors on the detrusor muscle of the bladder. This activation triggers a cyclic AMP pathway that relaxes the muscle during the storage phase, allowing the bladder to hold more urine and decreasing urgency and incontinence episodes.

The appropriate dose of Mirabegrón Stada is determined by the prescribing healthcare professional based on the patient’s medical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mirabegron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different class (β3‑adrenergic agonist) and does not have the anticholinergic side‑effects such as dry mouth or constipation that are common with anticholinergics. Clinical studies show comparable efficacy in reducing urgency episodes, and mirabegron may be preferred when anticholinergic tolerance is an issue.

Store Mirabegrón Stada at ambient temperature, preferably below 25 °C (77 °F). Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight to maintain product stability.

Mirabegrón Stada is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious adverse reactions, although rare, can include severe hypertension, urinary retention, tachycardia, angioedema and myocardial infarction. Patients should seek immediate medical attention if they experience symptoms such as a sudden rise in blood pressure, difficulty urinating, rapid heartbeat, swelling of the face or throat, or chest pain.

Mirabegron Stada is contraindicated in patients with uncontrolled hypertension, severe urinary retention, or known hypersensitivity to mirabegron or any tablet excipients. Caution is also advised for individuals with significant cardiovascular disease, severe renal impairment, or those taking strong CYP2D6 inhibitors.